ArticleThe European physical journal. Special topics2022
The changing economic relationship between some of the major COVID-19 impacted countries with prominent wealth: a comparative study from the view point of stock markets.
Article in The European physical journal. Special topics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present work, a study has been made over the prime stock indices of some fiscally prominent countries impacted by COVID-19. The countries are separated in two ways: (1) considering gross total number of infected cases-here seven mostly impacted countries with certain global economic influence are selected; (2) considering the concentration of the infected cases-here six major impacted countries with considerable influence are selected. This sort of categorization is itself a novel strategy which is capable of including some less populated, but severely impacted countries of economic importance. The objective of the present analysis is to comprehend the impact of COVID-19 on these markets and to recognize the effect of COVID-19 on mutual association and dependence between these markets. To add more flavour of reliability, we have taken a new and fresh strategy of fixing the time frames under consideration before and during COVID-19 pandemic as uniform. We have used both linear and nonlinear Granger causality analysis and employed generalized forecast error variance decomposition analysis to review the exogeneity and endogeneity of the individual markets. The present study shows that this pandemic has changed the underlying relationship: some exogenous stock markets have become endogenous and vice versa in the pandemic. Linear relationship has been reduced radically, whereas nonlinear relationship has been improved during the COVID-affected period. TASE, the highest returned and significantly uncorrelated index, emerged as the most exogenous market in the pre-COVID period, though it is nonlinearly endogenous in the long term, in the COVD-affected period. CAC 40 is the most endogenous market for the short term in both pre-COVID and COVID-affected period. B3 and NYSE, exogenous in the pre-COVID period, turned out to be linearly endogenous in the COVID-affected duration, whereas BIST 100 and BSE SENSEX are found to be exogenous markets in the COVID-affected period according to both linear and nonlinear causal analysis. They were also exogenous in the pre-COVID era for the short-term period, with BSE SENSEX exhibiting exogeneity anti-persistently for the COVID-affected period too. Association among the markets is more in long term rather than short term. A possible conclusion is also that the markets may regain long-term association once the effect of COVID would fade away.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.